Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial *.
Opal, Steven MD; Laterre, Pierre-Francois MD; Abraham, Edward MD; Francois, Bruno MD; Wittebole, Xavier MD; Lowry, Stephen MD; Dhainaut, Jean-Francois MD; Warren, Brian MD; Dugernier, Thierry MD; Lopez, Angel MD; Sanchez, Miguel MD, PhD; Demeyer, Ignace MD; Jauregui, Luis MD; Lorente, Jose Angel MD; McGee, William MD; Reinhart, Konrad MD; Kljucar, Sascha MD; Souza, Sonia PhD; Pribble, John PharmD; and the Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis (COMPASS) Investigators
Critical Care Medicine.
32(2):332-341, February 2004.
(Format: HTML, PDF)
Objective: Platelet-activating factor (PAF) and structurally-related oxidized phospholipids are proinflammatory mediators in systemic inflammatory states such as severe sepsis. The enzyme platelet-activating factor acetylhydrolase (PAF-AH) rapidly degrades PAF and oxidized phospholipids into inactive metabolites. Reduced PAF-AH activity has been observed in patients with severe sepsis and may contribute to their systemic inflammatory response and organ dysfunction. A previous clinical trial with recombinant human PAF-AH (rPAF-AH, Pafase) suggested that this treatment may decrease 28-day all-cause mortality in patients with severe sepsis. The current study was undertaken to confirm this result.
Design: A prospective, randomized, double-blind, placebo-controlled, multicenter, international trial.
Setting: One hundred forty-six intensive care units from nine countries.
Patients: Approximately 2,522 patients were planned to be enrolled <=12 hrs after the onset of severe sepsis. Eligible patients were randomized to receive either rPAF-AH 1.0 mg/kg or placebo administered intravenously once daily for five consecutive days.
Measurements and Main Results: The study was terminated based on the recommendation of an independent data and safety monitoring committee after the second of three planned interim analyses, and the enrollment of 1,425 patients. rPAF-AH treatment was well tolerated among the 1,261 patients included in the interim analysis (643 rPAF-AH and 618 placebo), but did not decrease 28-day all-cause mortality compared with placebo (25% for rPAF-AH vs. 24% for placebo; relative risk, 1.03; 95% confidence interval, 0.85-1.25; p = .80). There were no statistically significant differences between treatment groups in any of the secondary efficacy end points. The overall incidence of adverse events was similar among rPAF-AH and placebo-treated patients, and no rPAF-AH-treated patients developed antibodies to PAF-AH.
Conclusions: rPAF-AH was well tolerated and not antigenic, but did not decrease 28-day all-cause mortality in patients with severe sepsis.
(C) 2004 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins